Study guide
15.3 Patient-Specific Preparations
APC Intern Written Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Pathway to General Registration 1.3 Restricted Open-Book Strategy (AMH & APF) 1.4 Scoring, Results & Appeals
2 Legal Framework: PBS & Medicine Schedules
2.1 PBS, Authority Prescriptions & Special Access Scheme 2.2 Schedules 2 & 3 (Pharmacy & Pharmacist Only Medicines) 2.3 Schedules 4 & 8 (Prescription Only & Controlled Drugs)
3 Legal Framework: Privacy, National Law & Pharmacy Board
3.1 Privacy, Confidentiality & Patient Rights 3.2 Health Practitioner National Law & Registration 3.3 Pharmacy Board Codes, Guidelines & Standards
4 Patient-Centred Medication Management
4.1 Assessing Clinical Situations & Treatment Options 4.2 Patient Factors: Adherence, Efficacy & Safety 4.3 Drug & Dosage-Form Factors 4.4 Culturally Responsive Medication Management
5 Primary Care & Judicious Use of Medicines
5.1 Primary Care & OTC Assessment 5.2 Judicious Use of Antimicrobials & High-Risk Agents 5.3 Non-Pharmacological Options & Evidence-Based OTC Choices
6 Dispensing & Clinical Appropriateness
6.1 Prescription Evaluation 6.2 Clinical Appropriateness Checks 6.3 Labelling, Packaging & Dispensing Standards 6.4 Communicating with Prescribers & Documenting Changes
7 Counselling & Acute Care
7.1 Patient-Centred Counselling 7.2 Confirming Understanding & Lifestyle Counselling 7.3 Acute Illness, Injury & Emergency Response
8 Therapeutics: Cardiovascular & Endocrine
8.1 Hypertension & Heart Failure 8.2 Ischaemic Heart Disease & Anticoagulation 8.3 Diabetes Medicines 8.4 Thyroid & Lipid Disorders
9 Therapeutics: Infection, Respiratory & Gastrointestinal
9.1 Anti-Infectives & Infection Management 9.2 Asthma & COPD 9.3 Gastrointestinal & Hepatic Conditions 9.4 Vaccination & Travel Health
10 Therapeutics: Neurology, Psychiatry & Pain
10.1 Epilepsy & Movement Disorders 10.2 Depression, Anxiety & Psychosis 10.3 Pain Management & Opioids 10.4 Migraine & Common Analgesics
11 Therapeutics: Special Populations & Systems
11.1 Women's Health, Contraception & Pregnancy 11.2 Dermatology, Ophthalmology & ENT 11.3 Renal/Hepatic Impairment & Dose Adjustment
12 Therapeutics: Rheumatology, Haematology, Urology, Oncology & Toxicology
12.1 Rheumatology: Gout, Osteoarthritis & Inflammatory Arthritis 12.2 Haematology: Anaemias & Blood Safety Monitoring 12.3 Urology & Men's Health 12.4 Oncology Support & Oral Anticancer Medicines 12.5 Toxicology & Poisoning Management
13 Monitoring: Clinical Review
13.1 Clinical Review Process 13.2 Interpreting Laboratory & Clinical Monitoring 13.3 Recommending Treatment Modifications
14 Monitoring: Safety & Adverse Drug Reactions
14.1 Adverse Drug Reactions & Reporting 14.2 Allergies, Sensitivities & Cross-Reactivity 14.3 High-Risk Medicines Monitoring
15 Compounding Medicines
15.1 Determining Required Formulations 15.2 Compounding Standards & Quality 15.3 Patient-Specific Preparations
16 Pharmaceutical Calculations
16.1 Dosage Calculations 16.2 Concentrations, Dilutions & Alligation 16.3 Half-Life & Basic Kinetic Calculations
17 Promote Health & Well-Being
17.1 National & Local Health Priorities 17.2 Screening Programs & Pharmacist Role 17.3 Culturally Responsive Promotion & Self-Sufficiency
15.3 Patient-Specific Preparations
Key Takeaways Explain This Topic AI
Reconstituting a proprietary antibiotic powder per product information differs from designing a true compound from bulk ingredients; both still need correct diluent, storage, and expiry counselling.
Dermatological dilutions require clear final strength, suitable base, and counselling on application site, quantity, and duration—especially with potent corticosteroids.
Hormone and other high-risk topicals demand containment thinking, accurate strength, and caution about systemic absorption and household exposure.
Flavouring can improve paediatric adherence but must not undermine stability, dose accuracy, or allergy safety; always counsel on measuring devices.
Refuse or redesign unsafe compound requests (impossible stability, unnecessary high risk, sterile work without facilities, unclear strength) and offer alternatives.
Last updated: August 2026
14.3 Patient-Specific Preparations
Quick Answer: Translate formulation principles into patient cases . Distinguish manufacturer reconstitution of antibiotic powders from true compounding . Handle dermatological dilutions and high-risk hormone creams with clear strengths, containment, and counselling. Use flavouring thoughtfully for adherence. Teach use, storage, BUD, and measuring devices . Refuse requests that are unsafe, unnecessary, or outside competence—and document a safer plan. Use APF for methods and professional expectations under open-book exam conditions.
This section is application-focused. Intern Written items often present a parent, a dermatology prescription, or an unusual cream request and ask what you would do next.
- Case pattern A: Paediatric antibiotic suspension — reconstitution vs true compound
- Proprietary powder for reconstitution
Many antibiotics are supplied as a dry powder for oral suspension. The pharmacist (or supervised intern) adds a specified volume of water, shakes, and labels with the manufacturer’s in-use expiry and storage (often refrigerate; some are room temperature— check the product ).
Critical steps:
- Confirm the product matches the prescription (drug, strength after reconstitution)
- Use the correct total volume of diluent as per product information (not “about half a bottle of water”)
- Invert/shake as directed to disperse fully; inspect for lumps
- Label with patient directions, discard date , storage, and “shake well” if required
- Counsel on dose volume with an oral syringe, course length, food requirements, and missed doses
- Do not reconstitute far in advance of supply unless stock-control procedures justify it and stability allows
This is not designing a novel APF formula, but it is a high-frequency, high-error patient-specific preparation step. Wrong diluent volume → wrong strength → under- or overdosing.
True compound when no commercial liquid exists
If only tablets or capsules are marketed, a compounded oral liquid may be required. Then:
- Confirm no suitable licensed liquid exists
- Use an APF or evidence-based formula where available
- Choose vehicle and preservative appropriately for age
Calculate concentration so doses are measurable (for example aim for whole-mL or easy 0.5 mL increments when possible)
- Assign BUD and storage from APF/stability principles
- Document the batch record fully
- Counsel carers that this is a compounded medicine with a shorter dating period than many factory liquids
Exam distinction: reconstituting a registered powder kit ≠ inventing a suspension from crushed tablets. The clinical checks differ, but both demand accurate strength and clear dating.
- Case pattern B: Dermatological dilutions
- Example scenario
A prescriber orders a potent corticosteroid cream diluted to a lower percentage in a moisturising base for facial use in a teenager with sensitive skin.
Intern checklist:
- Check Action
- Clinical fit Face often needs lower potency/shorter duration; confirm indication
- Final strength Calculate and label the finished % clearly
- Base Compatible cream/ointment; patient acceptability
- Quantity Match area and duration; avoid excessive supply of potent steroids
- APF/method Follow accepted dilution practice; mix to uniformity
- Counselling Thin layer, site, duration, wash hands, when to review
- Safety net Worsening rash, skin thinning concerns, infection signs → medical review
Dilution is not always pharmacologically “linear” in clinical effect perception, but accurate preparation and labelling of the intended strength remain mandatory. Do not produce ambiguous labels such as “half strength cream” without stating the actual concentration.
Combination topicals
Combining antiseptics, steroids, and antifungals is sometimes requested. Assess evidence, compatibility, and whether separate commercial products applied in a planned sequence are safer. Unstable mixtures should be declined or reformulated with advice to the prescriber.
Case pattern C: Hormone and other high-risk creams (high-level cautions)
Hormone creams (for example oestrogen or testosterone preparations in compounded form), other potent actives, and sensitising agents require elevated controls:
- Accurate dosing and strength — small absolute errors can be clinically significant
- Containment and cross-contamination control during preparation
- Patient counselling on transfer risk (skin-to-skin contact with partners or children for some hormones)
- Application site and hand washing
- Systemic adverse effect awareness and review triggers
- Questioning unnecessary custom hormone combinations marketed without clear evidence
Interns should treat “bioidentical multi-hormone cream” requests with professional scepticism: verify the prescription, clinical indication, monitoring plan, and whether a registered product exists. Complex hormone compounding may be complex compounding best referred to specialist facilities.
Flavouring and adherence
Taste is a major reason children refuse medicines. Flavouring can help, but only within quality limits.
Good practice:
- Use flavour systems compatible with the vehicle and drug (APF/practice guidance)
- Avoid allergens relevant to the patient (e.g. specific food flavour proteins if pertinent)
- Do not add arbitrary kitchen ingredients that destroy stability or introduce microbes
- Re-check that flavouring volume does not meaningfully dilute strength unless the formula accounts for it
- Pair flavouring with correct measuring devices and demonstration
Adherence counselling beats endless reformulation: same time each day, reward routines, mask taste with compatible foods only if the drug allows (some antibiotics interact with dairy or require empty stomach—check AMH/product information).
Counselling on use and storage of compounded medicines
Every compounded supply needs counselling that is more explicit than many proprietary packs.
- Core counselling points
- What it is — medicine name, strength, that it was compounded for them
- How much and how often — demonstrate oral syringe or spatula technique
- How long — course length or review date; do not keep “for next time” beyond BUD
- Storage — fridge vs room temperature, protect from light/heat, keep out of children’s reach
- BUD / discard date — exact date; what to do with leftovers (return to pharmacy where appropriate)
Appearance changes — separation that does not resuspend, colour change, odd smell → do not use; contact pharmacy
- Missed doses and side effects — standard clinical counselling plus when to seek care
- Other medicines and allergies — confirm again at supply
Document counselling for high-risk preparations. Offer written instructions when literacy, language, or complexity warrants—plain English or interpreter support as needed (link to culturally responsive care from Standard 3.1).
When to refuse unsafe compound requests
Pharmacists may and must decline compounding that cannot be done safely or ethically.
Refuse or redesign when
- Problem Safer response
- Suitable proprietary product available Supply/recommend commercial product
- Strength or directions ambiguous Clarify with prescriber before making anything
Stability unknown and risk high Seek evidence, use APF standard formula, or refer specialist; do not guess long BUDs
- Sterile product requested without aseptic capability Refer to appropriate sterile facility
- Hazardous/complex compound beyond premises competence Refer; do not attempt containment on an open bench
Request appears recreational, non-therapeutic, or for another person without authority Apply legal/ethical supply rules; do not compound
- Patient expects factory shelf-life for a water-based compound Educate; do not mislabel
- Carer cannot measure the proposed concentration safely Redesign concentration or dose form
Communication tips: explain the patient-safety reason, offer alternatives (different form, commercial option, specialist compounder, prescriber discussion), and document the decision. Refusal is a professional act under Standards 1.3 and 3.4 , not rudeness.
Integrated mini-cases for exam thinking
Mini-case 1: Parent asks you to crush several adult warfarin tablets into a weekly syrup stored in a soft drink bottle. → Refuse that process: anticoagulant potency risk, stability/microbial risk, unsafe container, better to use measurable strengths with clear labelling and device education—or liaise for an appropriate formulary liquid if justified.
Mini-case 2: Prescription for clotrimazole/hydrocortisone combination cream when a registered combination exists. → Prefer proprietary product unless an excipient issue forces compounding.
Mini-case 3: Oncology oral liquid from hazardous crushed tablets in a community dispensary without closed-system protection. → Treat as complex/hazardous; refer to appropriate service; protect staff and carers.
Mini-case 4: Antibiotic powder reconstituted yesterday, left at wrong temperature overnight, parent asks if it is “still OK because it looks fine”. → Do not rely on appearance; follow product-specific stability; often replace and recounsel storage.
APF under open-book pressure for patient-specific work
When a case involves how to prepare or label a compound:
- Identify preparation type in APF
- Note method critical steps (order of mixing, warnings)
- Apply BUD/storage guidance concepts
- Cross-check clinical dose in AMH
- Choose counselling and refusal points that match quality standards
- Putting it together for the exam
Patient-specific compounding questions reward risk discrimination . Show you can reconstitute proprietary antibiotic powders correctly, dilute dermatologicals with transparent strengths, handle hormone/high-risk topicals cautiously, flavour only within quality limits, counsel on BUD and storage , and say no when requests are unsafe—while still solving the patient’s therapeutic need through alternatives.